Efficacy and safety of tocilizumab in RA patients in daily clinical practice: An retrospective observational study

Efficacy and safety of tocilizumab in RA patients in daily clinical practice: An retrospective observational study - REtrospective ACTemra Investigation for Optimal Needs of RA patients study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006956

Enrollment

250

Registered

2011-12-27

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)RA patients who fulfilled the ACR classification criteria. 2)RA patients administered tocilizumab for the first time between April 2008 and March 2009.

Exclusion criteria

Exclusion criteria: Patients who had functional class4 using Steinbrocker criteria.

Design outcomes

Primary

Measure	Time frame
Percentages of three different remissions; clinical remission (the disease activity score using the 28 joint count [DAS28]-ESR<2.6), structural remission (modified total Sharp score [mTSS]=/<0.5), and functional remission (health assessment questionnaire [HAQ]=/<0.5) at week 104 after tocilizumab treatment.	—

Countries

Japan

Contacts

Public ContactKAZUHISA NAKANO

University of Occupational and Environmental Health, Japan The First Department of Internal Medicine, School of Medicine

kazuhisa@med.uoeh-u.ac.jp0936031611

Outcome results